American International Group, Inc. Relmada Therapeutics, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$2.24 - $4.76 $589 - $1,251	263 Added 2.03%	13,219 $29,000
Q4 2022 Feb 10, 2023	SELL	$2.17 - $35.84 $101 - $1,684	-47 Reduced 0.36%	12,956 $45,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $3,367 - $6,811	184 Added 1.44%	13,003 $481,000
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $8,052 - $14,805	488 Added 3.96%	12,819 $243,000
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $67,080 - $108,283	4,012 Added 48.23%	12,331 $333,000
Q4 2021 Feb 11, 2022	SELL	$16.93 - $26.82 $4,215 - $6,678	-249 Reduced 2.91%	8,319 $187,000
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $3,519 - $5,597	161 Added 1.92%	8,568 $225,000
Q2 2021 Aug 13, 2021	SELL	$29.55 - $39.15 $4,018 - $5,324	-136 Reduced 1.59%	8,407 $269,000
Q1 2021 May 07, 2021	BUY	$31.52 - $39.28 $693 - $864	22 Added 0.26%	8,543 $301,000
Q4 2020 Feb 12, 2021	SELL	$29.88 - $39.8 $3,764 - $5,014	-126 Reduced 1.46%	8,521 $273,000
Q3 2020 Nov 04, 2020	BUY	$34.42 - $43.78 $1,652 - $2,101	48 Added 0.56%	8,647 $325,000
Q2 2020 Aug 12, 2020	BUY	$31.59 - $49.98 $271,642 - $429,778	8,599 New	8,599 $385,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.